Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lobelia chinensis** is a creeping perennial plant belonging to the Campanulaceae family, native to China and East Asia. It is regarded as one of the 50 fundamental herbs in Traditional Chinese Medicine (TCM) and used for conditions such as fever, acute inflammation, lung cancer, edema, snakebites, acute heart failure, and other ailments. Its mechanism of action is primarily anti-inflammatory and anti-oxidant, most notably through suppression of inflammatory cytokines (TNF-α, IL-1β, IL-6) and inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) via NF-κB pathway modulation[1][5][9]. Unlike Lobelia inflata, it does **not** contain lobeline[5]. Chemical constituents include piperidine alkaloids (excluding lobeline), coumarins, flavonoids, polyacetylenes, and alkaloid-lignan hybrids[3][5]. It exhibits diuretic, antispasmodic, and circulatory balancing properties and has demonstrated biological activities related to cancer, inflammation, bacterial and viral infections, and liver diseases[1][5][9]. Mild toxicity has been reported, with adverse reactions including nausea, vomiting, heartburn, anxiety, and, in larger doses, potentially severe effects[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lobelia chinensis.